Inclusion Criteria:

- Patients with stage T1 or T2 untreated adenocarcinoma of the prostate, with a Gleason
score that is less than or equal to 6, as well as a prostate-specific antigen (PSA)
between 10-20 (intermediate risk) or patients with stage T1 or T2 untreated
adenocarcinoma of the prostate, with a Gleason score that is equal to 7, as well as a
PSA equal to or less than 20 (intermediate risk).

- Zubrod performance status score of 0-1

- Patients must sign a consent form before starting the study.

- No evidence of regional disease

- Patients with a previous history of cancer are eligible on the condition that they
have been disease-free for more than five years.

- Non-invasive epidermoid cancers of the skin are eligible.

- The patient must be available for treatments and follow-up visits.

- No evidence of metastatic disease, confirmed by a negative bone scan.

Exclusion Criteria:

- Severe medical or psychiatric problems that may compromise study compliance

- Chronic hepatic disease; abnormal hepatic function, i.e. AST-ALT > 1.5 times the
upper normal limit.